Residual Breast Cancer Measurement Could Predict Long-term Survival, Study Reports

Residual Breast Cancer Measurement Could Predict Long-term Survival, Study Reports
A key measure of the breast cancer that's left after chemotherapy but before surgery could be used to come up with a long-term patient prognosis, according to a study. Doctors could apply the method to neoadjuvant -- or pre-surgery -- chemotherapy alone, or to a combination of chemotherapy and HER-2 targeted treatment, researchers said. The study, “Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype,” was published in the Journal of Clinical Oncology. There are two main measures of residual cancer. One is the yp-stage scale developed by the American Joint Commission on Cancer. The other is the residual cancer burden, or RCB, scale. W. Fraser Symmans and colleagues at the University of Texas wanted to know whether RCB could be an effective means of determining the long-term prognosis of breast cancer patients in two scenarios. One scenario was a patient receiving chemotherapy, then surgery. The other scenario was a patient receiving a combination of neoadjuvant chemotherapy and HER2-targeted treatment, then surgery. Symmans, MB, ChB, is professor of pathology and director of research operations at the University of Texas MD Anderson Cancer Center. The researchers evaluated three groups of breast cancer patients treated with Taxol (paclitaxel) followed by chemotherapy with fluorouracil, Adriamycin (doxorubicin), and cyclophosphamide. One cohort, known as T/FAC-1, consisted of the first 219 patients whose RCB scores were measured. The second, T/FAC-2, was a validation cohort for the initial RCB measurements. It was made up of 226 patients. The third coho
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.